Chemomab Advances Phase 3 Trial for Nebokitug, Targets Primary Sclerosing Cholangitis

Chemomab Therapeutics is advancing to a pivotal Phase 3 trial for nebokitug, a treatment for primary sclerosing cholangitis. The company has secured regulatory alignment with both the FDA and EMA, enhancing the trial's potential for success. Chemomab's financial metrics indicate strong balance sheet health but highlight challenges in profitability and revenue growth. The company's market capitalization is $14.02 million, and it operates within the biotechnology industry.